0001418135FALSE00014181352024-10-282024-10-28

(Exact name of registrant as specified in its charter)

(Address of principal executive offices, including zip code)

(Registrant’s telephone number including area code)

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-14(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Securities registered pursuant to Section 12(b) of the Act:

On October 28, 2024, Lubomira Rochet notified the Executive Chairman of the Board of Directors (the “Board”) of Keurig Dr Pepper Inc. (the “Company”) of her immediate resignation from the Board. Ms. Rochet's resignation did not result from any disagreement with the Company or the Board.

Also on October 28, 2024, the Board appointed Frank Engelen, Managing Partner and Chief Financial Officer of JAB Holding Company, as a member of the Board, effective immediately. Mr. Engelen will serve for an initial term to expire concurrently with the terms of the other members of the Board at the Company’s 2025 annual meeting of stockholders, or until his earlier death, resignation or removal. Mr. Engelen will not serve on any committees of the Board. There are no arrangements or understandings between Mr. Engelen and any other persons pursuant to which Mr. Engelen was appointed as a director, and Mr. Engelen is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933. Mr. Engelen will participate in the compensation arrangements for non-employee directors as described in the Company’s 2024 Proxy Statement filed with the SEC on April 26, 2024.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.